EZH2 and diffuse large B-cell lymphoma: Therefore, tazemetostat represents a valuable option with a reasonable toxicity profile and clinical efficacy for FL patients that are refractory to multiple prior lines, including those with WT EZH2. Preliminary results from the DLBCL portion of the trial (patient n = 226; EZH2 mutant, n = 36) were disappointing.